Form 4: Celldex Therapeutics Director Acquires Stock Options

Keith L. Brownlie, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• Keith L. Brownlie, a director of Celldex Therapeutics, Inc. (CLDX), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024.
• Brownlie acquired 16,500 non-qualified stock options with an exercise price of $36.43.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The options are exercisable from June 13, 2025, and expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates